Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05455697
Title Tafasitamab, Retifanlimab, and Rituximab in Combination With Chemotherapy (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for the Treatment of Diffuse Large B-cell Lymphoma
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Washington

diffuse large B-cell lymphoma

follicular lymphoma

B-cell lymphoma


Cyclophosphamide + Doxorubicin + Prednisone + Retifanlimab + Rituximab + Tafasitamab-cxix + Vincristine Sulfate

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.